

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 November 2021 (25.11.2021)



(10) International Publication Number
WO 2021/236676 A1

(51) International Patent Classification:

C07K 14/54 (2006.01) A61K 47/68 (2017.01)
A61K 47/65 (2017.01) C07K 16/24 (2006.01)

(21) International Application Number:

PCT/US2021/033014

(22) International Filing Date:

18 May 2021 (18.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/027,276 19 May 2020 (19.05.2020) US

(71) Applicant: **WEREWOLF THERAPEUTICS, INC.**
[US/US]; 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US).

(72) Inventors: **WINSTON, William**; c/o Werewolf Therapeutics, Inc., 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **SEIDEL-DUGAN, Cynthia**; c/o Werewolf Therapeutics, Inc., 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **HICKLIN, Daniel**; c/o Werewolf Therapeutics, Inc., 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **BRODKIN, Heather**; c/o Werewolf Therapeutics, 1030


Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **SALMERON-GARCIA, Jose Andres**; c/o Werewolf Therapeutics, Inc., 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **STEINER, Philipp**; c/o Werewolf Therapeutics, Inc., 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US).

(74) Agent: **UNDERWOOD, Robert H.** et al.; Hogan Lovells US LLP, 125 High Street, Suite 2010, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: ACTIVATABLE IL-12 POLYPEPTIDES AND METHODS OF USE THEREOF



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*